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Invasive Pulmonary Aspergillosis Goes Viral Again?
In the last decade, influenza emerged as a risk factor for invasive
pulmonary aspergillosis (IPA) in patients admitted to an ICU for
respiratory failure (1, 2). A case definition for influenza-associated
pulmonary aspergillosis (IAPA) was recently proposed by an expert
panel (3). However, the diagnosis of IPA in critically ill patients
remains challenging, and the current EORTC-MSG criteria were
not validated in immunocompetent ICU patients. Given that the
specificity of a positive Aspergillus culture of an upper airway
sample is low, measurement of galactomannan (GM) in BAL has
become an important diagnostic tool in ICU patients (4). The
increased awareness and the high mortality of IAPA has generated
worldwide concerns that IPA may also occur in critically ill
patients with coronavirus disease (COVID-19). Recently, studies
of COVID-19–associated pulmonary aspergillosis (CAPA)
reported incidences in the range of 3–33% (5, 6).
In this issue of the Journal, Fekkar and colleagues (pp. 307–317)
report on a retrospective study on the incidence of invasive pulmonary
fungal infections in 145 mechanically ventilated patients with COVID-19
(54% on extracorporeal membrane oxygenation) admitted to a large
ICU in a 1,850-bed tertiary care center in France (7). A probable
or putative invasive pulmonary mold infection was diagnosed
in seven patients (4.8%), and four died. The authors used
stringent definitions and did not consider an isolated positive
non–culture-based fungal diagnostic test or an isolated positive fungal
culture with negative follow-up cultures to be proof of infection. This
occurred in 25 patients (17.2%). Multivariate analysis found solid
organ transplantation and use of corticosteroids to be risk factors for
CAPA. The authors should be commended for the careful assessment
of CAPA and for providing detailed clinical and microbiological
information that helps in distinguishing infection from colonization or
a false-positive test result. Yet, as in previous CAPA publications, there
was no control group. This precludes definite conclusions on severe
COVID-19 being an independent risk factor for IPA. A recent elegant
study by Yusuf and colleagues compared the rate of any positive
Aspergillus test (culture, GM, or PCR) in patients admitted to the ICU
for influenza, pneumococcal pneumonia, or COVID-19 (8). A positive
Aspergillus test on BAL was observed in 18.8% of the patients with
influenza, 5.4% of the patients with COVID-19, and 4.6% of the
patients with pneumococcal pneumonia. Together with the data
provided by Fekkar and colleagues, this study suggests that COVID-19
may not pose a high risk for IPA.
Several possible reasons may explain why the incidence of
CAPA varies across studies. First, various definitions were used with
a heterogeneity of diagnostic criteria, including BAL and other
respiratory samples, such as tracheal aspirates or nonbronchoscopic
lavages. In contrast to the definition of IPA in classically
immunocompromised patients, the definition of IPA in critically
ill patients is associated with much more uncertainty. Second,
during the first wave of the pandemic, physicians were reluctant
to do aerosol-forming procedures including bronchoscopies in
critically ill patients with COVID-19. This explains why GM
testing on BAL was often unavailable. Third, the use of immune
modulating therapies and, in particular, corticosteroids, known to
be associated with an increased risk for IPA, varied substantially
between centers. In the study by Fekkar and colleagues, only 17% of
the patients received corticosteroid therapy, possibly leading to an
underestimation of the CAPA incidence. Now that dexamethasone
has become the standard of care for critically ill patients with
COVID-19, data on IPA in patients with COVID-19 collected later
into the pandemic will be required to take this into account (9).
IAPA has also been reported with variable incidences (1, 10).
The time window between ICU admission and diagnosis of
IAPA tends to be very short (median, 3 d), whereas CAPA seems
to occur later during ICU stay (median, 8–10 d) (11). From a
pathophysiological standpoint, severe influenza causes destruction
of the respiratory epithelium and of the associated ciliary function
necessary to brush out Aspergillus conidia, leading to extensive
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damage of the protective epithelial barrier against invasive
aspergillosis. Although COVID-19 enters the respiratory epithelium
via the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) ACE2 receptor, it does not cause epithelial damage to
the same extent as influenza but instead primarily leads to diffuse
alveolar and endothelial vascular cell damage with increased capillary
permeability and fluid leakage, resulting in congestion, edema, and
diffuse inflammatory infiltrates. These observations raise a number
of questions regarding the association between COVID-19 and IPA.
Most importantly, the demonstration of invasiveness of the infection
is lacking in most CAPA cases with some exceptions, such as the
study by Rutsaert and colleagues, in which Aspergillus trachea-
bronchitis was documented on biopsy in 3 of 34 patients
(12–14). On the other hand, Flikweert and colleagues found no
histopathological prove of CAPA in postmortem needle core lung
biopsies in six critically ill patients with COVID-19 with a GM index
on BAL between 1.7 and 5.7 optical density index (15). Another
argument against angioinvasion is the observation that serum GM
was positive in up to 60% of IAPA cases (1), but this seems to be
exceptional in CAPA. Furthermore, in the growing number of
publications with an ever-increasing number of COVID-19
autopsies, CAPA has been remarkably absent (16, 17). However, the
absence of hyphal invasion at autopsy may also be due to prolonged
antifungal therapy in the weeks preceding death. However hard this
may be, more autopsy data are needed, particularly from patients in
whom Aspergillus was detected in the week preceding death.
Overall, these data strongly suggest that the incidence of CAPA is
lower than that of IAPA. Indeed, the distinction between colonization
and angioinvasive disease may bemore difficult in CAPA because serum
fungal infection markers are often negative. It also underscores the
limitations of IPA definitions that rely almost solely on microbiological
data with direct or indirect detection of Aspergillus in respiratory
samples, particularly in clinical conditions with a low pretest probability
of IPA. Taking into account host factors, clinical risk and radiological
findings may help rise the pretest probability of IPA.
Apart from the uncertain diagnostic criteria and, as such, the
incidence of CAPA, other questions need to be addressed as well. Is
CAPA an independent risk factor for ICU mortality? Is the use of
corticosteroids for COVID-19 a risk factor? And if so, is it high
enough to start thinking about antifungal prophylaxis? Or will we be
able to use more targeted immune-modulation agents in the future,
such as anti–IL-6 drugs that may not pose a risk for IPA? Future
research will need to answer these questions and many others,
hopefully before a new virus appears and again leads to a new type of
viral-associated pulmonary aspergillosis in critically ill patients, with
or without corticosteroids. But the best scenario would be that, as of
2022, COVID-19 has become part of 21st century history. n
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Rethinking Alveolar Ventilation and CO2 Removal
“Yea, all things live forever, though at times they sleep and are
forgotten.”
H. Rider Haggard, She: A History of Adventure, 1887
I recall my mentor and coauthor (M.R.P.) sharing a personal story
from the 1970s. He had heard that Drs. Ted Kolobow and Luciano
Gattinoni had performed an extracorporeal carbon dioxide removal
(ECCO2R) experiment in sheep. They showed that pulmonary
ventilation progressively decreased until breathing ceased as CO2
removal with ECCO2R approached metabolic CO2 production (1).
This innovative work confirmed important principles of respiratory
drive and was groundbreaking enough for my mentor (a young
man at the time) to travel from Johns Hopkins in Baltimore to the
National Heart Institute in Bethesda and see it for himself. Fast
forward to the 21st century, and it is hard to imagine my fellows
showing such avid interest in CO2. In fact, clinicians today appear
to have a greater interest in oxygen physiology. This state of affairs
is entirely understandable; noninvasive bedside monitoring
provides us with regular information on oxygen status, whereas
acquisition of information on CO2 status generally demands more
commitment.
The current pandemic has exposed the impact of our
knowledge imbalance in this regard, because the mysterious “happy
hypoxia” reported in patients with coronavirus disease (COVID-19)
(2) is not nearly so mysterious when one considers the role of CO2
in determining respiratory drive (3). Along similar lines, patients
with end-stage chronic obstructive pulmonary disease are not so
much limited by hypoxia but by dyspnea from hypercapnia caused
by impaired alveolar ventilation (4). Under these circumstances,
respiratory dialysis with ECCO2R can increase CO2 removal, but
removing only the CO2 dissolved in blood cannot permit long off-
dialysis survival because stopping ECCO2R will cause CO2
concentrations to immediately rise. This therapeutic approach
seems doomed to failure unless the CO2 removed is not only that
stored in the blood and interstitium but from the entire body.
Relative to this concept, in this issue of the Journal, Giosa and
colleagues (pp. 318–327) report the findings of a physiology study
exploring CO2 kinetics, whole-body stores, and the impact of
ventilation and ECCO2R on both (5). Using a porcine model, they
measured exhaled CO2 and _VO2 as they altered VE and ECCO2R.
Armed with this information, they were able to use the respiratory
quotient to determine metabolic _VCO2 ( _VmCO2). Here lies a
potential limitation of the work because it was necessary to make
certain assumptions for _VmCO2 calculations as the experiment
progressed. The animals were subjected to different ventilatory
conditions for 48 hours, and the difference between exhaled
CO2 and metabolically produced CO2 was used to determine
changes that had occurred in CO2 stores. Animals were either
hyperventilated or hypoventilated. After 24 hours, some of the
hypoventilated animals received ECCO2R to supplement alveolar
ventilation, and some had ventilation returned to baseline. A key
observation of their work was that CO2 changes occurred in two
phases, as follows: a fast phase in which PCO2 rapidly changed in
blood, followed by a slow phase, which was revealed as a failure of
measured PCO2 to reach equilibrium even after 24 or 48 hours. So,
how do we interpret these two phases?
Perhaps the simplest data to understand is the fast phase, in
which blood and interstitial fluid quickly load or unload their CO2
stores. Assuming relatively constant metabolism, conventional
wisdom accepts that measured PCO2 reaches a new equilibrium
within 45 minutes of ventilatory changes (6). A quick glance at the
kinetics reported by Giosa and colleagues supports this; changes in
ventilation (or ECCO2R) are followed by a rapid change in PCO2
that plateaus within 15 minutes and changes little between 15 and
60 minutes. However, by continuing experimental conditions for
24 or 48 hours, the authors showed that PCO2 steadily increases or
decreases at 0.002–0.003 mm Hg/minute depending on whether
hypoventilation or hyperventilation is continued.
Importantly, during prolonged hypoventilation, the volume of
CO2 slowly accumulating in the body exceeded the amount present
(or stored) in the blood and interstitium. Similarly, during
hyperventilation, the volume of expired CO2 exceeded that which
can be explained by the sum of the metabolically produced CO2
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